Apoptosis
Apoptosis, also known as programmed cell death, is rigorously controlled process of cell death that leads to phagocytosis of unwanted cell. It is triggered after sufficient cellular damage and activated through extrinsic or intrinsic pathways. The intrinsic pathway is mainly occurs via release of cytochrome c from the mitochondria and regulates mitochondrial outer membrane permeabilization by Bcl-2 family proteins. The extrinsic pathway is induced by ligand binding to death receptor, such as Fas, TNFαR, DR3, DR4, and DR5. Caspases then cleave target proteins and nuclear lamins to promote DNA degradation, resulting apoptotic cells undergo phagocytosis. In addition, p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some Inhibitors of apoptosis proteins (IAPs), such as XIAP/BIRC4 and Bruce/BIRC6, can block casapse activity through direct binding, while other IAPs, such as cIAP1/BIRC2, cIAP2/BIRC3, act as ubiquitin ligases that target caspases for ubiquitin-mediated degradation. Apoptosis is essential for growth, development and aging in multicellular organisms. Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases, including cancer.
-
BA6105 MSU-42011Summary: MSU-42011 is an orally active retinoid X receptor agonist. -
BA6140 CA-170Summary: CA-170 is an oral dual inhibitor. -
BA6144 PD-L1-IN-1Summary: PD-L1-IN-1 is a potent inhibitor. -
BA6145 LatikafuspSummary: Latikafusp (AMG256) is a bifunctional fusion protein containing targeted antibodies and mutant proteins designed to provide pathway stimulation to PD-1+ cells. -
BA6146 AcasunlimabSummary: Acasunlimab (GEN1046) is a bispecific antibody (bsAb) that targets and. -
BA6147 D18Summary: D18 is an immunomodulator. -
BA6149 TPP-1Summary: TPP-1 is a potent inhibitor of the interaction. -
BA6150 BMS-37Summary: BMS-37 is an immune checkpoint inhibitor. -
BA6151 TagitanlimabSummary: Tagitanlimab has the potential to study recurrent or metastatic nasopharyngeal carcinoma (NPC). -
BA6152 PD-1-IN-24Summary: Inhibitors with oral activity.


